Security
Trxade Group, Inc. Common stock · TRXD
TRXDOTCCommon stockHistorical · closed Feb 12, 2020CIK 1382574Updated Nov 17, 2026
TRXD price & chart
This listing closed Feb 12, 2020. Live provider charts are shown only for current listings.
Current security: SCNX
About the company
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiaries, including Scienture, LLC is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture, LLC are across therapeutics areas, indications and cater to different market segments and channels. For more information xplease visit www.scienture.com.
In the news
No coverage from other publishers is available.
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Results of Operations and Financial Condition · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 2.02, 3.01, 9.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 3.03, 5.03, 7.01, 9.01
Show 5 more recent filings
DEF 14A filing
Regulation FD Disclosure
Items 7.01, 9.01
PRE 14A filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 104,830,290Source | 94,259,693Source | 87,734,007Source | 84,178,330Source | 14,848,533Source | 80,661,705Source | 84,178,330Source | 104,853,805Source | 84,178,330Source | 104,853,805Source | 12,532,913Source | 3,710,026Source |
| Property, Plant and Equipment, NetUSD | 16,000Source | 17,500Source | 14,500Source | 16,500Source | 6,500Source | 15,000Source | 17,000Source | 7,000Source | 15,500Source | 17,500Source | 277,009Source | 65,214Source |
| GoodwillUSD | 21,372,960Source | 7,848,747Source | — | 21,372,960Source | — | — | 21,372,960Source | — | — | 21,372,960Source | — | 0Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 76,400,000Source | 76,400,000Source | 70,065,371Source | 76,400,000Source | — | 70,519,218Source | 76,400,000Source | — | 70,973,064Source | 76,400,000Source | 8,962,688Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | 8,188,140Source | 15,391Source | — | — | — | 3,498,812Source | 6,662,008Source | — | 151,908Source | 1,133,633Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 590,050Source | 10,430Source | 385,313Source | — | 13,091Source | 722,545Source | 3,734Source | 6,937Source | 731,328Source | 11,106Source | 821,804Source | 728,964Source |
| Inventory, NetUSD | 234,521Source | 7,884Source | 203,074Source | — | 6,439Source | 210,934Source | — | 5,372Source | 213,408Source | — | 968Source | 119,582Source |
| Assets, CurrentUSD | 1,421,074Source | 7,255,916Source | 9,201,897Source | 856,625Source | 12,144,444Source | 4,774,044Source | 7,825,226Source | 14,026,816Source | 7,916,406Source | 6,305,477Source | 2,753,062Source | 2,093,123Source |
| Operating Lease, Right-of-Use AssetUSD | 23,360Source | 215,491Source | 2,468Source | 29,814Source | 175,550Source | 9,693Source | 186,909Source | 183,414Source | 23,360Source | 201,433Source | 529,623Source | 1,051,815Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 22,160,659Source | 9,127,652Source | 23,632,481Source | 26,434,370Source | 3,063,085Source | 13,841,265Source | 25,195,770Source | 3,120,363Source | 14,057,946Source | 25,781,684Source | 11,990,560Source | 3,367,159Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 231Source | 86Source | 410Source | 161Source | 14Source | 406Source | 125Source | 14Source | 406Source | 87Source | 9Source | 99Source |
| Additional Paid in CapitalUSD | 135,100,304Source | 117,008,196Source | 150,876,988Source | 126,683,845Source | 38,290,315Source | 150,773,535Source | 123,265,605Source | 38,289,871Source | 150,671,215Source | 118,111,007Source | 33,788,284Source | 20,482,573Source |
| Retained Earnings (Accumulated Deficit)USD | -52,430,904Source | -31,876,241Source | -86,775,872Source | -48,823,543Source | -26,504,881Source | -83,953,501Source | -42,102,970Source | -24,670,979Source | -80,551,237Source | -39,038,973Source | -33,245,940Source | -19,719,536Source |
| Stockholders' Equity Attributable to ParentUSD | 82,669,631Source | 85,132,041Source | 64,101,526Source | 77,860,464Source | 11,785,448Source | 66,820,440Source | 81,162,760Source | 13,618,906Source | 70,120,384Source | 79,072,121Source | 542,353Source | 763,136Source |
| Liabilities and EquityUSD | 104,830,290Source | 94,259,693Source | 87,734,007Source | 104,294,834Source | 14,848,533Source | 80,661,705Source | 106,358,530Source | 16,739,269Source | 84,178,330Source | 104,853,805Source | 12,532,913Source | 3,710,026Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 7,351,446Source | 5,413,438Source | 3,026,300Source | 7,688,199Source | 2,902,089Source | 2,803,670Source | 7,461,665Source | 2,951,387Source | 2,735,351Source | 7,906,893Source | 11,556,355Source | 2,146,791Source |
| Operating Lease, Liability, CurrentUSD | 24,137Source | 60,882Source | 2,546Source | 28,056Source | 32,608Source | 10,004Source | 65,843Source | 32,608Source | 24,137Source | 63,334Source | 139,705Source | 196,872Source |
| Accounts Payable, CurrentUSD | 3,672,860Source | 2,904,081Source | 916,771Source | 3,136,436Source | 726,266Source | 1,404,794Source | 3,184,771Source | 953,098Source | 1,443,266Source | 2,898,683Source | 2,082,054Source | 729,153Source |
| Operating Lease, Liability, NoncurrentUSD | — | 173,366Source | — | 2,546Source | 160,996Source | — | 138,919Source | 168,976Source | — | 156,469Source | 409,205Source | — |
| Deferred Income Tax Liabilities, NetUSD | 13,524,213Source | — | 11,037,595Source | 13,524,213Source | — | 11,037,595Source | 13,524,213Source | — | 11,037,595Source | 13,524,213Source | — | — |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 887,035Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -420,269Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 984,825Source | 1,042,892Source | 503,634Source | 1,800,093Source | 500,454Source | 703,872Source | 1,411,315Source | 493,398Source | 657,034Source | 1,313,731Source | 400,987Source | 290,013Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 16,052,838Source | 16,052,838Source | 143,430Source | — |
| Long-term DebtUSD | 2,000,000Source | — | — | 3,577,984Source | — | — | 3,092,462Source | — | — | 2,897,698Source | — | — |
| Prepaid Expense and Other Assets, Current | — | —Source | — | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -3,183,601Source | — | — | — | -3,063,997Source | — | 9,065,798Source | -17,843,574Source | -3,909,868Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | —Source | — | —Source | — | —Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 102,320Source | 437Source | 2,068,892Source | — | 29,738Source | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -8,783Source | -7,371Source | 720,222Source | 11,106Source | 293,784Source | -496,692Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -2,474Source | — | 213,408Source | -968Source | -4,232,947Source | 63,303Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -38,473Source | -113,913Source | -1,567,215Source | 448,572Source | 1,607,625Source | 252,125Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,919,255Source | -2,956,457Source | -13,379,683Source | -14,265,239Source | — | -1,525,929Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 27,552,791Source | — | -427,845Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 12,000Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -200,000Source | 4,697,999Source | 19,733,595Source | -12,979,770Source | — | -35,171Source |
| Dividends paid | — | — | — | — | — | — | — | — | — | —Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,119,255Source | 1,741,542Source | 6,353,912Source | 307,782Source | -942,986Source | -1,988,945Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 733,694Source | 336,206Source |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 814,790Source | — |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 453,846Source | — | 453,846Source | — | 814,790Source | 44,100Source |
| DepreciationUSD | — | — | — | — | — | — | 500Source | 500Source | 2,000Source | 2,000Source | 19,375Source | 14,637Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | 2,356,428Source | — | — | -662,916Source | — | 603,322Source | 2,296,834Source | 180,383Source | — | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | — | — | 4,100Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | -374,968Source | — | 4,100Source |
| General and Administrative ExpenseUSD | — | — | 2,165,398Source | 168,649Source | 368,790Source | 2,927,764Source | 1,074,864Source | 1,355,948Source | 7,926,016Source | 6,677,580Source | 2,785,633Source | 1,755,433Source |
| GoodwillUSD | — | — | 21,372,960Source | 7,848,747Source | — | 21,372,960Source | — | 21,372,960Source | — | 21,372,960Source | — | 0Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 26,346,050Source | — | 5,129,115Source | 792,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 792,500Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | -4,973,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -3,607,361Source | -3,183,601Source | -2,822,371Source | -6,720,573Source | -3,402,264Source | -3,063,997Source | -41,512,264Source | -18,244,480Source | -13,720,546Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -3,607,361Source | -3,183,601Source | — | -6,720,573Source | — | -3,063,997Source | -41,512,264Source | -18,244,480Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | 27,310,278Source | -4,123,028Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -1,994,878Source | -534,396Source | — | — |
| InterestExpenseNonoperatingUSD | — | — | 1,803,430Source | 217,433Source | 269,785Source | 653,493Source | 37,019Source | 670,784Source | 4,083,206Source | 1,335,631Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | — | — | 875,250Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,607,361Source | -3,183,601Source | -2,822,371Source | -6,720,573Source | -3,402,264Source | -3,063,997Source | -41,512,264Source | 9,065,798Source | -17,843,574Source | -3,472,099Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -437,769Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -3,472,099Source |
| Nonoperating Income (Expense)USD | — | — | 753,845Source | 314,190Source | -122,638Source | -1,562,667Source | 107,235Source | 507,320Source | -916,300Source | -4,077,861Source | -6,457,140Source | 514,427Source |
| Operating ExpensesUSD | — | — | 4,935,827Source | 3,501,674Source | 3,035,512Source | 5,157,906Source | 3,563,349Source | 3,571,990Source | 42,922,324Source | 14,707,020Source | 9,861,663Source | 9,875,511Source |
| Proceeds from Contributed CapitalUSD | — | — | — | — | — | — | — | — | — | — | — | 1,500,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 4,597,999Source | 26,293,039Source | 2,954,000Source | — | 130,918Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 9,840Source | — | — |
| Stock or Unit Option Plan ExpenseUSD | — | — | 144,565Source | 437Source | 0Source | 162,438Source | 0Source | 437Source | 307,439Source | 25,584Source | 29,738Source | 79,163Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 590,050Source | 64,861Source | 343,639Source | — | 56,325Source | 10,258Source | 431,609Source | 136,643Source | 8,272,214Source | 11,448,265Source |
| Cost of RevenueUSD | — | — | 15,429Source | 60,978Source | 7,860Source | — | 2,475Source | 9,585Source | 100,127Source | 130,638Source | 5,673,957Source | 5,997,049Source |
| Operating Income (Loss)USD | — | — | -4,361,206Source | -3,497,791Source | -2,699,733Source | -5,157,906Source | -3,509,499Source | -3,571,317Source | -42,590,842Source | -14,701,015Source | -7,263,406Source | -4,424,295Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -3,607,361Source | -3,183,601Source | — | -6,720,573Source | — | -3,063,997Source | -43,507,142Source | -18,778,876Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -1,994,878Source | -534,396Source | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -437,769Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,607,361Source | -3,183,601Source | -2,822,371Source | -6,720,573Source | -3,402,264Source | -3,063,997Source | -41,512,264Source | 9,065,798Source | -17,843,574Source | -3,472,099Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.19Source | -1.34Source | -0.07Source | -0.48Source | -0.08Source | -0.33Source | -2.7Source | 2.69Source | -23.35Source | -0.41Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.19Source | -1.34Source | -0.07Source | -0.48Source | -0.08Source | -0.33Source | -2.7Source | 2.48Source | -7.49Source | -0.41Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 18,957,653Source | 2,373,848Source | 39,615,815Source | 14,141,443Source | 40,630,815Source | 9,425,751Source | 15,347,312Source | 3,375,325Source | 764,058Source | 8,472,946Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 18,957,653Source | 2,373,848Source | 39,615,815Source | 14,141,443Source | 40,630,815Source | 9,425,751Source | 15,347,312Source | 3,653,609Source | 2,381,443Source | — |
| Interest Expense (non-operating)USD | — | — | 1,803,430Source | 217,433Source | 269,785Source | 653,493Source | 37,019Source | 670,784Source | 4,083,206Source | 1,335,631Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 453,846Source | — | 453,846Source | — | 814,790Source | 44,100Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | 461,571Source | — | 454,346Source | — | 491,781Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 2,165,398Source | 168,649Source | 368,790Source | 2,927,764Source | 1,074,864Source | 1,355,948Source | 7,926,016Source | 6,677,580Source | 2,785,633Source | 1,755,433Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 26,346,050Source | — | 5,129,115Source | 792,000Source |
| Gross ProfitUSD | — | — | 574,621Source | 3,883Source | 335,779Source | — | 53,850Source | 673Source | 331,482Source | 6,005Source | 2,598,257Source | 5,451,216Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -3,607,361Source | -3,183,601Source | -2,822,371Source | -6,720,573Source | -3,402,264Source | -3,063,997Source | -41,512,264Source | -18,244,480Source | -13,720,546Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -3,607,361Source | -3,183,601Source | — | -6,720,573Source | — | -3,063,997Source | -41,512,264Source | -18,244,480Source | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | -0.19Source | -1.34Source | — | -0.48Source | — | -0.33Source | -2.7Source | -5.41Source | -17.96Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | -0.19Source | -1.34Source | — | -0.48Source | — | -0.33Source | -2.7Source | -5.41Source | -5.76Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | 27,310,278Source | -4,123,028Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,198,346Source | 336,206Source |
| Interest Income, OtherUSD | — | — | 1,120Source | 29,445Source | 147,147Source | 63,148Source | 133,344Source | 25,442Source | 302,702Source | 135,337Source | 4,198Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -3,472,099Source |
| Nonoperating Income (Expense)USD | — | — | 753,845Source | 314,190Source | -122,638Source | -1,562,667Source | 107,235Source | 507,320Source | -916,300Source | -4,077,861Source | -6,457,140Source | 514,427Source |
| Operating ExpensesUSD | — | — | 4,935,827Source | 3,501,674Source | 3,035,512Source | 5,157,906Source | 3,563,349Source | 3,571,990Source | 42,922,324Source | 14,707,020Source | 9,861,663Source | 9,875,511Source |
| Research and Development ExpenseUSD | — | — | 169,344Source | 1,253,983Source | 1,166,605Source | 843,549Source | 793,984Source | 574,679Source | 1,956,270Source | 2,236,690Source | — | — |
Offerings
Registration 333-286399
Registration 333-283591
Filing attachments
ex99-1.htm · 8-K · 2026-11-19
Exhibit 99.1 SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™ Q3 2026 Revenue Increased Approximately 113% Year-Over-Year to $1.25 Million Arbli™ generated approximately $330,000 and $730,000 of Net Product Revenue for Q3 2026 and the first nine months of 2026 respectively Initial Wholesale Shipments of REZENOPY™ Generated Approximately $925,000 of Net Product Revenue Following Its August 2026 Launch Q3 2026 Gro…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-19
Exhibit 99.1 Continued Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additions supporting continued commercial expansion COMMACK, NY, Oct. 13, 2026 (GLOBE NEWSWIRE) - SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating com…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-07
Exhibit 99.1 Scienture Holdings, Inc. Announces Reverse Stock Split COMMACK, NY, September 30, 2026 (GLOBE NEWSWIRE) - SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has determined to effect …
Read attachment ↗ex99-1.htm · 8-K · 2026-08-20
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million Commenced Co…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-22
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) - SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distrib…
Read attachment ↗